Characterization of a novel potent and specific inhibitor of type V phosphodiesterase.
Guanosine cyclic 3':5'-monophosphate (cGMP) plays a crucial role in regulating vascular smooth muscle contractile state. In rat aortic smooth muscle cells (RSMC) three isozymes of phosphodiesterase (PDE) may be involved in the degradation of cGMP, namely PDE I, PDE III, and PDE V. To study the effective contribution of PDE V to the control of intracellular cGMP levels, a specific and potent PDE V inhibitor 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)pyrazolo[3, 4d]- pyrimidin-4-(5H)-one (DMPPO) was synthesized. DMPPO is a competitive inhibitor with respect to cGMP (Ki = 3 nM) and displayed high selectivity for PDE V as compared to other PDE isozymes. DMPPO strongly potentiated the cGMP response of atrial natriuretic peptide- or sodium nitroprusside-treated RSMC (EC50 = 0.5 microM). In addition, similar intracellular cGMP levels were obtained in the presence of a saturating concentration of DMPPO or 3-isobutyl-1-methylxanthine, a nonspecific PDE inhibitor, suggesting that cGMP is almost exclusively hydrolyzed by PDE V in RSMC. Stimulation of RSMC with atrial natriuretic factor resulted in accumulation of cGMP in the extracellular media. This egression was shown to be proportional to the intracellular level of cGMP and a first-order rate constant of 0.04 min-1 was determined for the egression process. DMPPO did not interfere with the efflux and allowed us to show that intracellular cGMP levels are mainly controlled by PDE V, rather than by egression in RSMC. DMPPO is, therefore, a useful tool for determining the role of PDE V in the control of cGMP levels in living cells and tissues.
Coste
H
H
Laboratoires Glaxo, Centre de Recherches, Les Ulis, France.
Grondin
P
P
D000493:Allopurinol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D002417:Cattle; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D007093:Imidazoles / Q000138:chemical synthesis / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000302:isolation & purification / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D009599:Nitroprusside / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects / Q000302:isolation & purification / Q000378:metabolism; D011688:Purinones / Q000494:pharmacology; D011810:Quinoxalines / Q000138:chemical synthesis / Q000494:pharmacology; D051381:Rats; D012680:Sensitivity and Specificity; D013268:Stimulation, Chemical
C097114:1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one; C097113:1-isobutyl-3-methylimidazo(1,5-a)quinoxalin-4(5H)-one; D007093:Imidazoles; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D011688:Purinones; D011810:Quinoxalines; D009599:Nitroprusside; D000493:Allopurinol; D009320:Atrial Natriuretic Factor; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; C011145:zaprinast; D006152:Cyclic GMP